Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardlytics, Inc.CDLX · Entity 7603 | Chief Financial Officer | May 15, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardlytics, Inc.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 317,930 |
Ending reported balance
After 2026-05-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-15 · Purchase · Acquired 150,000 · Balance 267,930 F1: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1). Row 2 · 2026-05-18 · Purchase · Acquired 50,000 · Balance 317,930 F2: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2). |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.639 to $0.650, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1).
F2: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.627 to $0.639, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 53,757 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · derivative · entry 9 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 53,757 shares Expires 2026-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F7 · derivative.exercise_date: This option became exercisable with respect to one quarter (1/4) of the shares of stock subject to this option on June 15, 2017 (the "Initial Vesting Date"). The option becomes exercisable in respect of the remaining shares in thirty-six (36) equal monthly installments commencing one (1) month after the Initial Vesting Date, provided the Reporting Person continuously provides service to the Issuer through each vesting period. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 5,777 | $87.68 | $506,527.36 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 8 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,810 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F6 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $87.44 to $88.11, inclusive. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 9,937 | $86.97 | $864,220.89 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 7 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,587 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $86.44 to $87.43, inclusive. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 24,635 | $85.80 | $2,113,683.00 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 6 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,524 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $85.44 to $86.40, inclusive. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 30,425 | $85.06 | $2,587,950.50 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 5 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,159 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $84.44 to $85.43, inclusive. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 29,096 | $83.99 | $2,443,773.04 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,584 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $83.43 to $84.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 25,781 | $30.44 | $784,773.64 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 28,906 | $20.00 | $578,120.00 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 53,757 | $20.00 | $1,075,140.00 |
DisclosureSEC source: 0001666071-20-000018 · wf-form4_158025118636869.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 23:55 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,000 | $85.02 | $255,060.00 |
DisclosureSEC source: 0001666071-20-000009 · wf-form4_157913252579532.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,236 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 600 | $63.38 | $38,028.00 |
DisclosureSEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,236 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F5 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $63.01 to $63.52, inclusive. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,665 | $62.29 | $166,002.85 |
DisclosureSEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,836 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.94, inclusive. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 12,115 | $61.60 | $746,284.00 |
DisclosureSEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,501 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.99, inclusive. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 6,620 | $60.36 | $399,583.20 |
DisclosureSEC source: 0001666071-20-000002 · wf-form4_157808530520015.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,616 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 21:26 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,000 | $57.00 | $171,000.00 |
DisclosureSEC source: 0001666071-19-000181 · wf-form4_157653156760441.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,236 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 13:52 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,586 | $60.00 | $155,160.00 |
DisclosureSEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,236 F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 13:52 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · derivative · entry 5 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2024-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 13:52 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,414 | $60.00 | $144,840.00 |
DisclosureSEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,822 F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 13:52 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 17,000 | $55.94 | $950,980.00 |
DisclosureSEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,236 F2 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 13:52 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 22,500 | $9.08 | $204,300.00 |
DisclosureSEC source: 0001666071-19-000178 · wf-form4_157555395506220.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 702 shares of Common Stock acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 6,540 | $56.20 | $367,548.00 |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,034 F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of the performance stock units. F4 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.79, inclusive. Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 14,741 | $55.88 | $823,727.08 |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,574 F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of the performance stock units. F3 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $55.72 to $55.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes and (4) to this Form 4. Read SEC document |
| November 25, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionPerformance Stock Unit · Derivative | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 7 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Sock · 21,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019, twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification. F6 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the stock price target ("stock price tranche"). Fifty percent (50%) of the shares subject to the stock price tranche of the awarded PSU vested upon the Certification and were delivered on November 25, 2019, twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the stock price tranche of the awarded PSU will vest 12 months after the Certification. Read SEC document |
| November 25, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionPerformance Stock Unit · Derivative | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 6 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Sock · 21,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification. F5 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification. Read SEC document |
| November 25, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantPerformance Stock Unit · Derivative | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · derivative · entry 5 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Sock · 43,750 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification. F5 · derivative.expiration_date: On November 25, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a minimum cumulative adjusted EBITDA target over a trailing 12-month period of the Issuer's common stock was achieved (the "Certification") resulting in the award of the tranche of the PSU grant related to achieving the adjusted EBITDA target ("EBITDA tranche"). Fifty percent (50%) of the shares subject to the EBITDA tranche of the awarded PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the EBITDA tranche of the awarded PSU will vest 12 months after the Certification. Read SEC document |
| November 25, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 21,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 25, 2019 Filed Nov 28, 2019 00:12 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 21,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-19-000165 · wf-form4_157489991695486.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 21:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,000 | $57.12 | $171,360.00 |
DisclosureSEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,000 | $47.65 | $95,300.00 |
DisclosureSEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 5,000 | $50.00 | $250,000.00 |
DisclosureSEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 5,000 | $55.00 | $275,000.00 |
DisclosureSEC source: 0001666071-19-000149 · wf-form4_157385462500696.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 23:02 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 5,000 | $41.26 | $206,300.00 |
DisclosureSEC source: 0001666071-19-000138 · wf-form4_157264933882343.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $41.2501 to $41.292, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,906 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · derivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,906 shares Expires 2026-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 6,906 | $40.00 | $276,240.00 |
DisclosureSEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| October 29, 2019 Filed Oct 30, 2019 20:15 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 3,906 | $20.00 | $78,120.00 |
DisclosureSEC source: 0001666071-19-000136 · wf-form4_157246651030050.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| October 15, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 31,962 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · derivative · entry 7 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906 Underlying: Common Stock · 31,962 shares Expires 2026-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| October 15, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 3,000 | $37.15 | $111,450.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 5 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| October 15, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 21,555 | $37.50 | $808,312.50 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 4 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,565 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · kind: Shares sold to satisfy exercise cost and withholding tax obligations upon the exercise of employee stock option. Read SEC document |
| October 15, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 31,962 | $20.00 | $639,240.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 3 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,631 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · derivative · entry 6 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,868 Underlying: Common Stock · 1,631 shares Expires 2026-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,100 | $37.50 | $41,250.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,158 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. F2 · kind: Shares sold to satisfy exercise cost and withholding tax obligations upon the exercise of employee stock option. Read SEC document |
| October 11, 2019 Filed Oct 15, 2019 21:23 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 1,631 | $20.00 | $32,620.00 |
DisclosureSEC source: 0001666071-19-000128 · wf-form4_157117458093002.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 21:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,000 | $35.00 | $70,000.00 |
DisclosureSEC source: 0001666071-19-000126 · wf-form4_157013827835003.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,627 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 23, 2019. Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 21:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantPerformance Stock Unit · Derivative | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-19-000107 · wf-form4_156702626589539.xml · derivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Sock · 43,750 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the first tranche of the PSU to be awarded, which shares are reflected in Column 5 above. Fifty percent (50%) of the shares subject to the first tranche of the PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 12 months after the Certification. The PSU has not yet settled. F2 · derivative.expiration_date: On August 26, 2019, the Compensation Committee of the Issuer's Board of Directors certified that a target minimum trailing 30-day average closing price of the Issuer's common stock was achieved (the "Certification") resulting in the first tranche of the PSU to be awarded, which shares are reflected in Column 5 above. Fifty percent (50%) of the shares subject to the first tranche of the PSU vested upon the Certification, twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 6 months after the Certification, and twenty-five percent (25%) of the shares subject to the first tranche of the PSU will vest 12 months after the Certification. The PSU has not yet settled. Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 20:26 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001666071-19-000097 · wf-form4_156650555845317.xml · derivative · entry 2 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Sock · 10,000 shares Expires 2024-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 20:26 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 10,000 | $9.08 | $90,800.00 |
DisclosureSEC source: 0001666071-19-000097 · wf-form4_156650555845317.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 11:14 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $33.93 | $50,895.00 |
DisclosureSEC source: 0001666071-19-000091 · wf-form4_156621323159130.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,627 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018. Read SEC document |
| July 15, 2019 Filed Jul 15, 2019 22:04 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $28.14 | $42,210.00 |
DisclosureSEC source: 0001666071-19-000066 · wf-form4_156322823672024.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,127 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018 Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:38 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $25.18 | $37,770.00 |
DisclosureSEC source: 0001209191-19-038039 · doc4.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,627 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $24.96 to $25.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 15, 2019 Filed May 17, 2019 22:00 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 1,500 | $19.99 | $29,985.00 |
DisclosureSEC source: 0001209191-19-031090 · doc4.xml · nonDerivative · entry 1 Evans David Thomas · CIK 0001730451 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,127 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2018. F2 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 963 shares of the Common Stock acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.